Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting extra-articular organs, manifesting as symmetric polyarticular invasive joint inflammation. The disease pathogenesis involves cell death caused by lysis, known as pyroptosis, leading to the development of inflammation. Cytokines that promote inflammation, such as IL-18 and IL-1β, are released as a result of the NLRP3 inflammasome activating caspase (CASP)1, 3 and 4. Notably, the gasdermin D (GSDMD)-N-terminal allows substances to flow through the plasma membrane, and this protein is cleaved by CASP1 and other caspases. The present study aimed to evaluate the role of salivary CASP1 and GSDMD in the pathophysiology of RA, and determine the roles of the salivary flow rate and saliva pH. A control group and two groups of patients, including newly diagnosed and treated patients with RA, were enrolled in the present study. An independent rheumatologist rated the clinical disease activity score of each patient, and the saliva pH and salivary flow rate were also measured. In addition, ELISA was used to detect the expression levels of CASP1 and GSDMD. The results of the present study revealed that the CASP1 level was significantly increased in all patients with RA, compared with the control group. Notably, the levels of CASP1 differed between the treated patients with RA and those newly diagnosed with RA. The results also revealed that there were no significant differences in the levels of GSDMD between the groups. Moreover, there were significant differences in the mean saliva pH and salivary flow rate between all patients with RA and the control group. On the whole, the present study demonstrates that GSDMD and CASP1 may be required for the development of RA. Following the activation of CASP1, the development of RA is promoted via signals that amplify inflammatory responses. Understanding the specific roles of these signals may lead to the development of novel therapeutic approaches.
rheumatoid arthritiscaspase-1gasdermin Dsalivary flow rateFunding: No funding was received.Introduction
Extra-articular organ involvement and symmetric polyarticular invasive joint inflammation are hallmarks of rheumatoid arthritis (RA), a chronic systemic inflammatory disorder. RA is characterized by synovitis (1). At present, 0.5-1.0% of patients present with RA worldwide, with greater prevalence rates observed in females and the elderly (2). RA involves immune cells and cytokines that trigger an inflammatory response, leading to damage in the arthritic joint (3,4). However, the pathophysiology of RA remains to be fully understood. At present, research is focused on the involvement of the inflammasome within rheumatic disorders. Pathogen pattern-recognition receptors (PRRs) form multimeric complexes on the inflammasome, and bind to damage-associated molecular patterns and pathogen-associated molecular patterns to facilitate host defense responses. In the majority of cases, pro-caspase (CASP)1, PRR and a protein adapter form the inflammasome (5). Following activation, CASP1 inhibits the binding between pro-IL-1, pro-IL-18 and gasdermin D (GSDMD), resulting in pyroptosis and in an inflammatory response (6). Moreover, following the activation of the inflammasome, GSDMD is cleaved into the GSDMD-N-terminal. Cleavage is promoted canonically or non-canonically via external stimuli or endogenous damage (7,8). GSDMD-induced pyroptosis protects the host from bacterial invasion (9). Numerous inflammatory diseases exhibit persistent inflammation mediated by abnormal GSDMD activation (10).
Temporomandibular joint disorders (11), and symptoms of dry mouth are oral complications associated with RA (12,13). In addition, patients with RA may experience extra-articular involvement of the skin, eyes, heart, lungs, kidneys, neurological system and gastrointestinal tract (14). Individuals with clinically diagnosed RA may also experience changes in salivary function (15). In the majority of the affected organs, extra-articular symptoms of RA are caused by vascular vasculitis, which may be followed by arterial occlusion and vessel wall necrosis (14). The present study aimed to evaluate the role of salivary CASP1 and GSDMD in the pathophysiology of RA, and determine the potential associations between RA, saliva pH and salivary flow rate.
Subjects and methodsSubject information
Patients with RA (aged 20-60 years) were divided into two groups. The first group included 20 patients with a clinical diagnosis of RA who were not receiving any type of treatment from a rheumatologist (the newly diagnosed group). The second group included 40 patients with RA who had previously been treated with biological or non-biological Disease-modifying antirheumatic drugs (DMARD) in the Rheumatology Unit of the Baghdad Teaching Hospital (Baghdad, Iraq; treated group). Notably, rheumatologists in this unit evaluated the disease activity of all patients in each group using clinical disease activity score (CDAI).
Patient data was obtained, including name, age, sex, alcohol consumption, smoking history, family history, a history of systemic disorders and previous medications. In total, the control group included 16 male and 44 female participants. All patients in the control group were in good overall health, with no systemic disorders or immunological diseases and no previous medication. The age and sex of the individuals in the control group were matched to those of the RA groups. Patients were excluded from the present study according to the following criteria: An age >60 years, a history of smoking, alcoholism, or pregnancy at the time of the study.
All groups were examined between December, 2022 and mid-June, 2023. The present study was approved by the Institutional Review Board Ethics Committee at the College of Medicine, Al-Nahrain University, Baghdad, Iraq (ethics approval no. 20221029). The examination and collection of samples from patients with RA was approved by The Ministry of Health, Iraq. Written informed consent was obtained from all patients, and the Declaration of Helsinki was followed.
Assessment of disease activity using CDAI
In the Rheumatology Unit of The Baghdad Teaching Hospital, rheumatologists used CDAI to evaluate the disease activity of patients with RA (16).
Saliva collection
Unstimulated saliva collection was carried out according to the guidelines described by Tenovuo and Lagerlof (17). Samples were centrifuged for 10 min at 804.96 x g at room temperature (~20˚C), and divided into two groups for ELISA. Supernatants were stored at -200˚C until use in further experiments.
Calculation of salivary flow rate
All unstimulated saliva was collected from patients for 5 min. Volume was calculated and expressed as ml/min (18).
Determination of saliva PH
A digital pH meter with a single electrode was used to measure saliva pH (Jenway pH meter 3320) (19).
Detection of salivary CASP1
Salivary CASP1 was evaluated using ELISA, following the manufacturer's instructions (cat. no. ELK2076; ELK Biotechnology). Briefly, a microtiter plate was pre-coated with anti-CASP1 antibody (cat. no. ELK2076; ELK Biotechnology). Following the addition of samples, a biotin-conjugated anti-CASP1 antibody was added to the microtiter plate. Following incubation with primary antibodies for 50 min at 37˚C, the samples were incubated with horseradish peroxidase (HRP)-conjugated avidin (part number: ELK2076). TMB substrate solution (ELK Biotechnology, Co., Ltd.) was added to all wells, and color changes were observed in wells containing CASP1, biotin-conjugated antibody and enzyme-conjugated avidin. Changes in color were determined using a spectrophotometer (Thermo Fisher Scientific, Inc.) at 450±10 nm, and the enzyme-substrate reaction was terminated following the addition of sulphuric acid solution (ELK Biotechnology, Co., Ltd.). The optical density of the samples was read and compared with a standard curve to determine the concentration of CASP1.
Detection of salivary GSDMD
Salivary GSDMD was evaluated using ELISA, following the manufacturer's instructions (cat no. E6838Hu, Bioassay Technology Laboratory). Briefly, a plate was pre-coated with the anti-GSDMD antibody, and biotinylated human anti-GSDMD antibody was subsequently added. Following incubation with primary antibodies (provided with the kit) for 60 min at 37˚C, the samples were incubated with HRP-conjugated streptavidin, washed and substrate solution was added. Color development was indicative of human GSDMD. An acidic stop solution was added to all samples, and the absorbance was determined at 450 nm (using a spectrophotometer, Thermo Fisher Scientific, Inc.).
Statistical analysis
SPSS (version, 26; IBM Corp.) was used for statistical analysis. Differences between two groups were determined using unpaired Student's t-tests, and differences between multiple groups were determined using one-way ANOVA followed by a post hoc test (Duncan's multiple range comparisons). Percentage changes were determined using the Chi-squared test. Pearson correlation coefficient (r) was used to calculate the correlation between parameters. Receiving operating characteristics curve (ROC) analysis was used to determine the diagnostic capability of a binary discrimination system which plot the TPR (true positive rate) sensitivity against the false positive rate (1-specificity). A value of P<0.05 was considered to indicate a statistically significant difference.
ResultsDemographic characteristics of the study participants
The results of the present study revealed no significant differences in the age and sex of the participants between all groups. The mean disease duration in the treated RA group was 8.95±5.123 years. In addition, there was no significant difference in CDAI between the newly diagnosed and treated RA groups. The results of the present study demonstrated significant differences in the mean salivary flow rate and saliva pH between all patients with RA and the control group (Table I).
Detection of salivary CASP1and GSDMD
The results of the present study revealed a significant difference in the mean salivary CASP1 levels between all three groups, with 2.0134, 1.8665 and 1.5183 ng/ml observed in the treated RA, newly diagnosed and control groups, respectively. In addition, the mean salivary CASP1 level was notably higher in the newly diagnosed group compared with the control group. However, there was no significant difference in the mean salivary CASP1 level between the treated RA and newly diagnosed groups (Table I).
In addition, the results of the present study revealed that the mean salivary GSDMD levels were 3.4849, 3.1514 and 3.2260 ng/ml in the treated RA, newly diagnosed and control groups, respectively; however, differences between groups were not significant. In addition, there were no notable differences in the means of GSDMD and CASP1 in the saliva of the two groups of RA when these were divided according to disease activity score to low, moderate and high activity (Table II). Moreover, the results demonstrated no notable correlation between CASP1, GSDMD, saliva pH or salivary flow rate (Table III).
Diagnostic value of CASP1 and GSDMD
ROC analysis was used to determine the diagnostic value of CASP1 and GSDMD in patients with RA. CASP1 in the treated group revealed an area under the curve (AUC) of 0.7 (P=0.001), while GSDMD was not found to be efficient. At a 1.525 cut-off, CASP1 could predict the inflammation and disease activity in the treated RA group at a sensitivity of 78% and specificity of 63%. By contrast, the results of the ROC analysis demonstrated that CASP1 and GSDMD were not associated with disease activity in the newly diagnosed group (Fig. 1).
Discussion
The results of the present study demonstrated that RA often affects adults during their 40th decade of life, which is consistent with the results of the study by Ranade and Doiphode (20). The results of the present study revealed no significant differences in age or sex between the three study groups, which was comparable with the results of the study by Al Ghuraibawi et al (21). In the present study, the majority of patients with RA were female, which was also consistent with the study by Alkazzaz (22). The prevalence of RA may be higher among females due to gene silencing on the X chromosome, which plays a key role in the development of autoimmune disease. Notably, skewed inactivation may lead to differences in gene silencing in the maternal and paternal X chromosomes, resulting in distinct self-antigens that trigger a greater immune response. The reactions between self-antigens promote the development of auto-immune reactions, and the development of disease, such as RA (23).
The present study revealed that the salivary flow rate was significantly increased in patients with RA, compared with the control group. This outcome is consistent with the study conducted by Majid et al (24). This suggests that the salivary glands are one of the main target organs of RA, since RA is considered to be associated with the infiltration of lymphocytes of affected glands, leading to decreased chemical and salivary changes (25). In the present study, there were no appreciable changes between the newly diagnosed and treated patients with RA; however, the salivary pH increased significantly in the two patient groups compared with the control group. The study by Fadhil and Ahmed (26), which discovered a substantial decrease in salivary pH levels between the treated RA and control groups, is in conflict with this conclusion. The findings of that study demonstrated that an increase in the physiological salivary pH range corresponds to an increase in saliva flow rate and vice versa (26). The results of the present study revealed that patients with RA exhibited increased levels of salivary CASP1 compared with the control group, and these results were comparable with those obtained in the study by Kim et al (27). However, Karabulut et al (28) observed the opposite result.
Kim et al (27) investigated the reason behind the increase in CASP1 levels in the serum of patients receiving treatment for RA. They found that CASP1 activation is a sign of inflammasome activation, which is crucial for inducing an inflammatory response in macrophages. suggests that the RA drug may have an effect on CASP1 expression. The therapeutic strategy may affect CASP1 expression and activity (29). In the present study, the median value of salivary CASP1 in the newly diagnosed group was higher than that in the control group, which suggests the involvement of CASP1in the early stages of RA development. There were no significant differences in the median value of salivary CASP1 between the treated and newly diagnosed groups. This result is in accordance with the result presented in the study by Cascão et al (30).
The results of the present study demonstrated that there were no notable differences in the mean salivary GSDMD levels between the three groups. To the best of our knowledge, the present study is the first to investigate the levels of GSDMD in the saliva of patients with RA. Notably, Zhang et al (31) investigated the synovial expression of cleaved GSDMD using immunohistochemistry and multiplex immunohistochemistry. The results of the study by Zhang et al (31) demonstrated that patients with RA exhibited increased inflammasomes and GSDMD-N-terminal in the synovium, compared with patients with osteoarthritis. This result is in disagreement with that of the study conducted by Al Obaidi and Al Ghurabi (32), which discovered elevated levels of NLRP3, which caused the release of GASDMD in the patient group (periodontitis).
Of note, a limitation of the present study was that the concentrations of CASP1 (inactive form) and GSDMD (inactive form) were quantified in saliva. Nevertheless, the active forms were not quantified. Thus, further studies are required to further investigate these parameters.
In conclusion, the findings of the present study provide valuable insight into the role of GSDMD and CASP1 in the context of RA. The significance of these differences in the means of CASP1 indicate that it could be a critical factor in the severity and progression of RA. This aligns with existing literature that highlights the importance of inflammatory mediators in the pathogenesis of RA, suggesting that CASP1 may be a potential target for therapeutic intervention.
Acknowledgements
The authors would like to thank Dr Ali Hussein and Dr Adnan Sadkhan, Rheumatologists at the Rheumatology Unit of the Baghdad Teaching Hospital for their great contribution in the assessment of the severity of rheumatoid arthritis in patients depending on the clinical disease activity score.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Authors' contributions
WLA was involved in the conception and design of the study, in the literature search, in clinical analysis, data analysis, statistical analysis, and in the preparation and reviewing of the manuscript. AFAH was involved in the conception and design of the study, in data analysis, and in the preparation and reviewing of the manuscript. BHAG was involved in the conception and design of the study and was also involved in the preparation and reviewing of the manuscript. WLA and BHAG confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.
Ethics approval and consent to participate
The present study was approved by the Institutional Review Board Ethics Committee at the College of Medicine, Al-Nahrain University, Baghdad, Iraq (ethics approval no. 20221029). The examination and collection of samples from patients with RA was approved by The Ministry of Health, Iraq. Written informed consent was obtained from all patients, and the Declaration of Helsinki was followed.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesScottDLWolfeFHuizingaTWJRheumatoid arthritisLancet3761094110820102087010010.1016/S0140-6736(10)60826-4RudanISidhuSPapanaAMengSJXin-WeiYWangWCampbell-PageRMDemaioARNairHSridharDPrevalence of rheumatoid arthritis in low- and middle-income countries: A systematic review and analysisJ Glob Health501040920152596973210.7189/jogh.05.010409AlippeYMbalavieleGOmnipresence of inflammasome activities in inflammatory bone diseasesSemin Immunopathol4160761820193152017910.1007/s00281-019-00753-4AldhaherZAl-GhurabiBAlwanBHSerum levels of IL-22 and ACPA in patients with rheumatoid arthritisJ Pure Appl Microbiol126876912018BrozPDixitVMInflammasomes: Mechanism of assembly, regulation and signallingNat Rev Immunol1640742020162729196410.1038/nri.2016.58BoucherDMonteleoneMCollRCChenKWRossCMTeoJLGomezGAHolleyCLBierschenkDStaceyKJCaspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activityJ Exp Med21582784020182943212210.1084/jem.20172222ShiJZhaoYWangKShiXWangYHuangHZhuangYCaiTWangFShaoFCleavage of GSDMD by inflammatory caspases determines pyroptotic cell deathNature52666066520152637500310.1038/nature15514AbdullahWLAl-HashimyAFAl-GhurabiBHRamakrishnanMFocus on the Function and mechanism of pyroptosis in rheumatoid arthritisAl-Salam J Med Sci328362024WangJDeobaldKReFGasdermin D protects from melioidosis through pyroptosis and direct killing of bacteriaJ Immunol2023468347320193103676510.4049/jimmunol.1900045WangJYaoJLiuYHuangLTargeting the gasdermin D as a strategy for ischemic stroke therapyBiochem Pharmacol18811458520213393034810.1016/j.bcp.2021.114585GaribBTQaradaxiSSTemporomandibular joint problems and periodontal condition in rheumatoid arthritis patients in relation to their rheumatologic statusJ Oral Maxillofac Surg692971297820112176420010.1016/j.joms.2011.02.131GuobisZBasevicieneNPaipalienePNiedzelskieneIJanuseviciūteGAspects of xerostomia prevalence and treatment among rheumatic inpatientsMedicina (Kaunas)44960968200819142054AbdullaWLA-GhurabiBHGathwanKHAn Impairment of salivary gland function in rheumatoid arthritis: Association with change in salivary biomarkers and disease activityJ Bagh Coll Dent281651702016CojocaruMCojocaruIMSilosiIVrabieCDTanasescuRExtra-articular manifestations in rheumatoid arthritisMaedica (Bucur)5286291201021977172TorresSRPedrazasCHCorreiaMPde AzevedoMNLZamprognoTSilvaA JrGonçalvesLSPapiJADrugs or disease: Evaluating salivary function in RA patientsBra Oral Res30e10620162773736010.1590/1807-3107BOR-2016.vol30.0106Van der HeijdeDMVan't HofMVan RielPLVan de PutteLBDevelopment of a disease activity score based on judgment in clinical practice by rheumatologistsJ Rheumatol2057958119938478878TenovuoJLagerlofFSaliva. In: Thylstrup A, Fejerskov O (eds). Textbook of clinical cariology. 2nd edition. Copenhagen: Munksgaard, pp17-43, 1994.NavazeshMKumarSKSUniversity of Southern California School of DentistryMeasuring salivary flow: Challenges and opportunitiesJ Am Dent Assoc139 (Suppl)35S40S20081846067810.14219/jada.archive.2008.0353BaligaSMuglikarSKaleRSalivary pH: A diagnostic biomarkerJ Indian Soc Periodontol1746146520132417472510.4103/0972-124X.118317RanadeSBDoiphodeSIs there a relationship between periodontitis and rheumatoid arthritis?J Indian Soc Periodontol1622272012Al GhuraibawiZAGSharquieIKGorialFIA novel link of serum IL-39 levels in patients with rheumatoid arthritisIraqi J Sci64165116612023AlkazzazAMHIncidence of rheumatoid arthritis [2001 to 2011]Iraqi Postgrad Med J125685722013ValenciaMSex and gender in rheumatoid arthritis: considering a risk factor hierarchyCornell Undergrad Res J123292022MajidAYTalalSAbdullaWLEstimation of some salivary elements in rheumatoid arthritis patientsInt J Adv Res313172016NaglerRMSalamehFReznickAZLivshitsVNahirAMSalivary gland involvement in rheumatoid arthritis and its relationship to induced oxidative stressRheumatology (Oxford)421234124120031289085810.1093/rheumatology/keg362FadhilHNMAhmedKMEvaluation of salivary anti-CCP in relation to some oral manifestations in rheumatoid arthritis patients, Sulaimaniyah, Iraq. Res Sq: 1-18, 2023.KimSHLeeJHJeongHJKimJMBaekWKKimTHJunJBSonCNClinical significance of elevated serum caspase-1 levels in patients with ankylosing spondylitisAnn Lab Med4229329520223463562410.3343/alm.2022.42.2.293KarabulutGKitapçıoğluGÖzçakaÖAlpözENalbantsoyAKoçanaoğullarıHGücenmezSKeserGKabasakalYSaliva levels of caspase-1, TNF-α, and IFN-γ in primary Sjögren's syndrome: Oral mucosal abnormalities revisitedTurk J Med Sci4855455920182991425210.3906/sag-1710-31MannaSKMukhopadhyayAAggarwalBBResveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidationJ Immunol1646509651920001084370910.4049/jimmunol.164.12.6509CascãoRPolido-PereiraJCanhãoHRodriguesAMNavalhoMRaquelHNeves-CostaAMourãoAFResendeCda SilvaJACaspase-1 is active since the early phase of rheumatoid arthritisClin Exp Rheumatol30144201222272579ZhangXWangQCaoGLuoMHouHYueCPyroptosis by NLRP3/caspase-1/gasdermin-D pathway in synovial tissues of rheumatoid arthritis patientsJ Cell Mol Med272448245620233738679510.1111/jcmm.17834Al ObaidiMJAl GhurabiBHPotential role of NLRP3 inflammasome activation in the pathogenesis of periodontitis patients with type 2 diabetes mellitusJ Med Chem Sci65225312023
ROC curve analysis of CASP1 and GSDMD in patients with RA. For the treated group (left panel), the AUC for CASP1 was 0.7 (P=0.001) with optimal stratification achieved at a 1.525 cut-off value; for GSDMD, the AUC was 0.54. For the newly diagnosed patients (right panel), both tests were not efficient at predicting disease activity. ROC, receiver operating characteristic; AUC, area under the curve; CASP1, caspase-1; GSDMD, gasdermin D.
Demographic and clinical characteristics of the patients (treated and newly diagnosed patients) and the controls.